Lanean...
Emicizumab for the treatment of haemophilia A: a narrative review
One of the most serious complications of the treatment of severe haemophilia A is the development of alloantibodies against exogenous factor VIII (FVIII). Inhibitors render factor replacement therapy ineffective, exposing patients to a remarkably high risk of morbidity and mortality. Besides the wel...
Gorde:
| Argitaratua izan da: | Blood Transfus |
|---|---|
| Egile Nagusiak: | , , , , , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Edizioni SIMTI - SIMTI Servizi Srl
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6596376/ https://ncbi.nlm.nih.gov/pubmed/31246563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2450/2019.0026-19 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|